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A B S T R A C T
Background: Actinic keratosis (AK) affects one quarter of over 60 year olds in Europe with the risk of trans-
forming into invasive squamous cell carcinoma. Daylight photodynamic therapy (dPDT) is an effective and
patient preferred treatment that uses sunlight to clear AK. Currently, there is no standardised method for
measuring the light received during treatment.
Methods: SmartPDT® is a smartphone-based application and web-portal, developed by siHealth Ltd, enabling
remote delivery of dPDT. It uses satellite imagery and computational algorithms to provide real-time determi-
nation of exposure to PpIX-effective solar radiation (“light dose”). The application also provides forecast of
expected radiant exposures for 24- and 48-hs prior to the treatment period. Validation of the real-time and
forecasted radiant exposure algorithms was performed against direct ground-based measurement under all
weather conditions in Chilton, UK.
Results: Agreement between direct ground measurements and satellite-determined radiant exposure for 2-h
treatment was excellent at−0.1 %±5.1 % (mean ± standard deviation). There was also excellent agreement
between weather forecasted radiant exposure and ground measurement, 1.8 %±17.7 % at 24-hs and 1.6
%±25.2 % at 48-hs. Relative Root Mean Square of the Error (RMSEr) demonstrated that agreement improved as
time to treatment reduced (RMSEr= 22.5 % (48 -hs), 11.2 % (24-hs), 5.2 % (real-time)).
Conclusion: Agreement between satellite-determined, weather-forecasted and ground-measured radiant ex-
posure was better than any existing published literature for dPDT. The SmartPDT® application and web-portal
has excellent potential to assist with remote delivery of dPDT, an important factor in reducing risk in an elderly
patient population during the Covid-19 pandemic.
1. Introduction
Field change carcinogenesis, as a result of chronic sun exposure,
manifests as actinic keratosis (AK). It is extremely common, affecting 11
% to 26 % of individuals over 60-years-old in the USA, Europe and the
UK, with prevalence increasing linearly between 60 and 80 years of age
[1–4]. If left untreated, there is a reported 0.1% to 20% annual risk that
individual AKs will develop into invasive squamous cell carcinoma
[5,6]. Furthermore, most affected individuals will have multiple AKs
which, along with increased severity, increases the risk of progression
to skin cancer. For example, multiple severe AK (≥10) on the scalp
raises the cumulative risk of developing squamous cell carcinoma by
13.6 % [6]. Hence, there is a need for treatment.
Daylight photodynamic therapy (dPDT) is widely used in Europe,
Australia and South America as an effective, patient preferred treat-
ment for superficial AKs affecting field areas on the face and scalp
[7–9]. It is also becoming an increasingly popular therapy in Northern
America [10] due to its effectiveness and association with high levels of
patient satisfaction [7,11,12]. Complete clearance rates of 70 % were
reported by Lacour et al. following a single dPDT treatment in a mul-
ticentre European study [13] and Rubel et al. reported a complete
clearance rate of 89 % in an equivalent study in Australia [7]. dPDT
involves topical application of a photosensitiser pro-drug to the area of
diseased skin. The pro-drug is absorbed and metabolised to the
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photosensitiser, protoporphyrin-IX (PpIX), in the dysplastic cells
[14–16]. The PpIX is photoactivated when exposed to the visible and
long-wavelength ultraviolet radiation components of natural daylight.
A photochemical reaction then takes place in the presence of oxygen,
producing oxidative stress, inflammation and subsequent cell death.
The outcome is effective clearance of diseased tissue [14].
In dPDT, it is common practice to define the effective light dose as
the PpIX-weighted effective irradiance combined with the treatment
time [10,17]. Exposure is administered over a 2-h period when weather
conditions are favourable and a minimum PpIX-weighted radiant ex-
posure (“light dose”) of 8 Jcm−2 can be achieved [8,9,18–23]. A lack of
control of the received light dose could result in under-exposure, par-
ticularly in geographical locations with, and during periods of, variable
weather conditions [10,20,24]. These issues necessitate the need for
procedural improvement incorporating reliable and accurate mon-
itoring of AK-received light dose.
SmartPDT® is a smartphone-based application and a web-portal that
aims to improve the reliability and simplicity of dPDT delivery. The
application uses satellite-based near real-time monitoring of PpIX ac-
cumulated effective dose received by the patient. It also accounts for
the impact of sunscreen on effective dose and reduces the risk of sun-
burn during dPDT by monitoring erythema effective solar UV exposure.
Additionally, the web-portal, a tool developed for the clinician, will
predict radiant exposures both 48- and 24-hs prior to a potential
treatment. It will also be used to monitor ongoing therapy sessions via
an automatic connection to the active patients’ application.
The objective of this study was to determine the accuracy of the
algorithms used in the commercial SmartPDT® application by com-
parison of real-time and forecasted PpIX-effective radiant exposure with
direct ground measurements. Validation of algorithms for erythema
effective exposures was reported previously [25] and not included in
this paper.
2. Methods
2.1. Satellite imagery determination of PpIX-effective irradiance
The method developed by siHealth Ltd. (Harwell Campus, UK) is
based on near real-time determination of the PpIX-effective irradiance
by acquiring the optical imagery from several Earth Observation sa-
tellite sensors (geostationary and low earth orbit) [25]. These multi-
source satellite data are fused, and a downscaling model is applied to
achieve a temporal resolution of 1min, a spatial resolution in the range
1–12 km depending on latitude. Using more than one satellite source as
an input for clouds, ozone and aerosols allows the expansion of existing
models [26–29] to the PpIX action spectrum and all weather conditions
which is particularly important for climates with highly variable
weather such as the UK. This model is further development of a pre-
viously reported method for the near real-time monitoring of erythema
effective ultraviolet radiation [25].
Certain elements of this approach are similar to Wald [30] who
extended methodology for the computation of site-specific solar irra-
diance (ESRA) by using satellite-based total shortwave solar irradiance
and substituting the sunshine duration input with a new input, the
satellite-based “clearness factor” (expressing the turbidity of the at-
mosphere) calculated by using Meteosat Second Generation data. In
contrast, the proprietary method developed by siHealth Ltd. applies
radiative transfer model directly to the PpIX action spectrum and the
relevant atmospheric components (clouds, ozone, aerosols). The PpIX
action spectrum used in this research is the spectral absorption of PpIX
dimethyl ester in chloroform [31].
2.2. Weather forecast determination of PpIX-effective irradiance
The determination of forecasted PpIX-effective irradiance for 24-
and 48-hs in advance of the 2-h treatment period is achieved by
utilising the above model, replacing satellite imagery with meteor-
ological numerical weather predictions of cloudiness, ozone density and
aerosols optical depth; forecast of cloudiness is provided by MetOffice
(Exeter, UK), while the prediction of ozone and aerosols optical depth is
provided by the Copernicus Atmosphere Monitoring Service (CAMS)
(https://atmosphere.copernicus.eu/). The temporal resolution of the
forecasted PpIX effective irradiance in this case is hourly, the spatial
resolution is approximately 4 km in Europe and about 17 km world-
wide. The same methodology could also be used to estimate the PpIX
effective irradiance in clear-sky conditions on a larger timescale (e.g.
weeks or months) by using archived data on the ozone and aerosols
optical depth derived from the weekly average in the last 5 years.
Real-time and forecasted data were determined in 15-minute in-
tervals during the UK dPDT treatment season from 1st August to 26th
October 2018 and 31st March to 31st May 2019 under all weather
conditions for Chilton (51.575N, 1.318W), UK.
2.3. Ground-based measurement
Ground-based measurements of PpIX effective irradiance were
performed by Public Health England at the same location as indicated
above (Chilton, UK) using Glacier X TE-cooled CCD array spectro-
radiometer (BWTek, Newark, NJ, USA), coupled by optical fibre to a
D7-SMA diffuser (Bentham Instruments, Reading, UK).
2.4. Comparison
Two-hour PpIX-weighted radiant exposures (“light dose”) produced
by satellite imagery and weather forecasting were compared to the
ground-based measurements using a custom MATLAB script. Data
below 2 Jcm−2, significantly lower than the International guidelines
minimum criteria for dPDT [32], were excluded and only data from
0800 to 1700, representing clinical operating hours, were considered.
Ground measured radiant exposure was set as the reference and the
percentage differences from the SmartPDT® application calculated. To
evaluate performance of satellite imagery algorithms, Mean Bias Error
MBE, relative Mean Bias Error MBEr, Standard Deviation STDE, relative
Standard Deviation STDEr, Root Mean Squared Error RMSE, relative
Root Mean Squared Error RMSEr, Mean Absolute Error MAE, relative
Mean of Absolute Error MAEr and Goodness-of-fit R2 were calculated.
3. Results
3.1. Real-time radiant exposure (“light dose”)
Fig. 1a shows scatter plot of satellite imagery vs direct ground
measurements for 2-h dPDT, statistical analysis is given in Table 1 for
all data and as a detailed breakdown for treatment at different times of
the day.
Satellite imagery demonstrated excellent correlation with direct
ground measurements under all weather conditions and range of ex-
posures. The goodness-of-fit is above 98 % for the whole dataset and all
treatment periods; average percentage difference is -0.13 % with ab-
solute average percentage difference of 4.00 % and there is sub-
stantially no bias (MBEr< 0.6 %).
3.2. 24h and 48 h forecasted light dose
Fig. 1b shows the scatter plot of satellite imagery vs direct ground
measurements for 24-h forecast and Fig. 1c for 48-h forecast; statistical
analysis is given in Table 2 for the 24-h forecast and Table 3 for 48-h
forecast.
The mean percentage difference between 24-h forecasted data and
ground is 1.77 % with an absolute average percentage difference of
11.7 %. Goodness-of-fit is above 93 % for all data and all treatment
periods. 48-h forecast is marginally poorer with mean percentage
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difference from ground measurement of 1.57 % and absolute percen-
tage difference of 19.4 %. Goodness-of-fit for all data is 80 % and is
above 74 % for each treatment period. It should be stressed that per-
formance of forecasted dPDT model depends on weather forecast and
not on live data, therefore its outcome is unavoidably linked to the
accuracy of weather forecasting.
4. Discussion
dPDT is an effective treatment for the common pre-malignant
condition of chronic photodamaged skin and AK. However, the light
dose received by the patient is not routinely monitored in clinical
practice due to the lack of a simple standardised method. It is, there-
fore, not known what solar ultraviolet radiation exposure the patient
has received or whether the minimum effective PpIX radiant exposure
has been reached. Indeed, the proposed minimum effective light dose
has not been robustly determined in the literature due to limited data
and inaccurate dosimetry [24].
The most accurate dosimetry approaches are often costly, require
expertise to operate and are appropriate for environmental rather than
Fig. 1. Satellite predicted PpIX-effective radiant exposure for 2-h dPDT versus direct ground measurements. Data below 2 Jcm−2 excluded due to lack of clinical
relevance. a) Real-time b) 24-h forecasted and c) 48-h forecasted.
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personalised measurement [7]. Personalised approaches are less accu-
rate, do not determine the radiant exposure at the treatment site and
require post-acquisition processing [24,33].
Manley et al. [34] estimated the experimental errors associated with
four different methods of dosimetry, including the O’Mahoney et al.
method [18]. They concluded that use of spectroradiometers results in
the lowest total error on effective light dose calculation, provided the
patient is in the vicinity of the spectroradiometer. Therefore, for prac-
tical reasons Manley et al. recommended the O’Mahoney et al. method,
with a 95 % confidence interval of± 14.3 % and a maximum error
of± 28 % [34]. SmartPDT® has a lower error than the O’Mahoney et al.
method (95 % confidence interval± 10.2 % and a maximum error of
18 % for dPDT doses≥8 Jcm−2) and is more convenient requiring only
a smartphone without additional measurement device.
The importance of a simple non-detector based determination of
radiant exposure has also been identified by LaRochelle et al. who
developed a model determining effective dose based on easily acces-
sible local weather data [10]. Their practical solution is aimed at de-
livery of dPDT indoors, through glass, to negate low temperatures and
wind chill. La Rochelle et al. model showed strong correlation between
the meteorological factors and the PpIX-weighted irradiance (R2=87
%) but was not as strong as our model (R2> 98 %). We believe that the
model we present here is the most accurate and practical method
available for PpIX-weighted radiant exposure determination.
To our knowledge, SmartPDT® is also the only system to forecast the
PpIX-effective light dose, which will greatly assist with treatment
planning. Determining the future light dose relies upon weather fore-
cast information, which becomes less accurate the further in the future
one tries to predict. Inaccuracies in weather prediction are represented
by the increase in RMSEr at 24-hs (11.2 %) and 48 -hs (22.5 %). The
goodness-of-fit also deteriorates with increasing time to treatment
(R2= 94 % at 24-hs and 80 % at 48-hs). Precision of forecast data is not
as critical as real-time determination of light dose as forecasted light
dose will be used, along with additional factors such as predicted
rainfall and ultraviolet exposure, to select potentially appropriate
treatment times. Additional and improved forecast information may
help improve the precision of the model.
Currently, the SmartPDT® algorithm is similar to many of the other
reported dPDT dosimetry techniques, determining radiant exposure in
the horizontal plane (i.e. pointing directly upwards). This cannot be
regarded as the true light dose to the surface of the lesion because the
orientation of the lesion(s) will vary in relation to the solar position.
Manley et al. demonstrated that, in extreme circumstances, measure-
ment in the horizontal plane could under-represent the true received
radiant exposure by 78 % [34]. Further work is required to consider the
position of the lesion and determine radiant exposure on the surface of
the affected area.
The current application is also limited in its spatial resolution of
1–12 km; higher spatial resolution is achieved at the equator and de-
creases towards northerly latitudes. The analysis presented here results
in agreement that is acceptable clinically in the UK.
In conclusion, we present a verification of the satellite-imagery and
weather-forecast determination of PpIX-weighted radiant exposure by
SmartPDT® application. SmartPDT® has the potential to assist with
treatment planning and deliver accurate real-time dosimetry for dPDT
creating a more convenient and reliable therapy. This may lead to
further improvement in the accuracy of forecasted data, the geo-
graphical resolution and the light dose received in any treatment plane.
Table 1
Statistical indexes of PpIX-weighted dose calculated by real-time satellite imagery and measured ground data under all weather conditions for dPDT at different time
of the day.
All data 2h treatment period
08:00−10:00 09:00−11:00 10:00−12:00 11:00−13:00 12:00−14:00 13:00−15:00 14:00−16:00 15:00−17:00
Number of data points 3913 263 530 532 525 525 521 520 497
Mean radiant exposure (Jcm−2) 15.6 12.7 14.9 17.2 18.4 18.4 16.7 14.0 10.9
MBE (Jcm−2) −0.0247 0.036 0.0301 −0.073 −0.096 −0.046 −0.0178 0.0070 −0.0065
MBEr −0.16% 0.29 % 0.20 % −0.42% −0.52% −0.25% −0.11% 0.05 % −0.06%
STDE 0.81 0.68 0.85 0.97 1.00 0.88 0.77 0.63 0.53
STDEr 5.20 % 5.37 % 5.68 % 5.62 % 5.44 % 4.77 % 4.63 % 4.47 % 4.84 %
RMSE 0.81 0.68 0.85 0.97 1.01 0.88 0.77 0.63 0.53
RMSEr 5.21 % 5.38 % 5.69 % 5.64 % 5.46 % 4.78 % 4.63 % 4.47 % 4.84 %
MAE 0.60 0.50 0.62 0.74 0.77 0.67 0.59 0.47 0.38
MAEr 3.84 % 3.91 % 4.14 % 4.31 % 4.19 % 3.66 % 3.52 % 3.37 % 3.43 %
R 0.994 0.994 0.993 0.991 0.991 0.993 0.994 0.995 0.995
R2 0.988 0.988 0.985 0.983 0.982 0.987 0.989 0.990 0.990
Table 2
Statistical indexes of PpIX-weighted dose calculated by 24 -h forecasted satellite imagery and measured ground data under all weather conditions for dPDT at
different time of the day.
All data 2h treatment period
08:00−10:00 09:00−11:00 10:00−12:00 11:00−13:00 12:00−14:00 13:00−15:00 14:00−16:00 15:00−17:00
Number of data points 3892 261 525 532 524 525 520 515 490
Mean radiant exposure (Jcm−2) 15.7 12.8 15.0 17.2 18.5 18.4 16.7 14.1 11.1
MBE (Jcm−2) 0.147 −0.35 0.035 0.46 0.56 0.49 0.294 −0.094 −0.52
MBEr 0.93 % −2.74% 0.24 % 2.65 % 3.04 % 2.63 % 1.76 % −0.66% −4.65%
STDE 1.75 1.56 1.69 1.91 1.96 1.92 1.75 1.59 1.44
STDEr 11.15 % 12.22 % 11.22 % 11.11 % 10.63 % 10.43 % 10.45 % 11.27 % 12.95 %
RMSE 1.76 1.60 1.69 1.96 2.04 1.98 1.77 1.59 1.52
RMSEr 11.19 % 12.52 % 11.22 % 11.42 % 11.05 % 10.76 % 10.60 % 11.29 % 13.76 %
MAE 1.41 1.24 1.36 1.53 1.63 1.56 1.39 1.29 1.15
MAEr 8.95 % 9.68 % 9.05 % 8.91 % 8.80 % 8.47 % 8.28 % 9.14 % 10.42 %
R 0.971 0.972 0.969 0.966 0.966 0.967 0.971 0.971 0.972
R2 0.943 0.944 0.940 0.934 0.934 0.934 0.944 0.943 0.945
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Importantly, in a therapy where there is no standardised simple dosi-
metry measure, SmartPDT® offers accurate and accessible technology to
increase confidence in the delivery of effective dPDT.
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